Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
3.47
Nov 20 • 3:59 PM ET Dollar change+0.07 Percentage change(2.06%)
Aftermarket Close
3.47
Aftermarket • 5:00 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
3.68M
Enterprise Value
2.83M
Income
-8.66M
Sales
0.10M
Book/sh
2.22
Cash/sh
0.90
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
3
IPO
Jan 29, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
36.78
P/B
1.56
P/C
3.87
P/FCF
-
EV/EBITDA
-
EV/Sales
28.28
Quick Ratio
0.76
Current Ratio
0.76
Debt/Eq
0.04
LT Debt/Eq
0.01
Option/Short
No / Yes
EPS (ttm)
-8.81
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
46.11% 31.85%
Sales past 3/5Y
-48.38% -44.27%
EPS Y/Y TTM
-3.77%
Sales Y/Y TTM
-45.76%
EPS Q/Q
18.74%
Sales Q/Q
-71.39%
Insider Own
0.03%
Insider Trans
0.00%
Inst Own
1.54%
Inst Trans
1.96%
ROA
-115.52%
ROE
-151.69%
ROIC
-362.44%
Gross Margin
52.26%
Oper. Margin
-3142.13%
Profit Margin
-8312.79%
SMA20
6.82%
SMA50
8.72%
SMA200
-39.35%
Trades
Shs Outstand
1.06M
Shs Float
1.06M
52W High
10.43 -66.73%
52W Low
2.56 35.55%
Volatility
12.61% 10.19%
ATR (14)
0.51
RSI (14)
51.82
Beta
1.46
Rel Volume
0.04
Avg Volume
500.85K
Volume
18,225
Perf Week
-14.53%
Perf Month
19.98%
Perf Quarter
-14.32%
Perf Half Y
-49.19%
Perf YTD
-55.05%
Perf Year
-56.08%
Perf 3Y
-44.92%
Perf 5Y
-97.56%
Perf 10Y
-
Prev Close
3.40
Price
3.47
Change %
2.06%
Consensus
Sell
Avg. Price Target
$22.87
Implied Upside
+559.1%
Analysts1incl. previous ratings
Rating Distribution1 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 31, 2024Upgrade
HH.C. Wainwright
Neutral → Buy$30+764.6%
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.
Chief Medical Officer & DirectorDr. Roger G. Mills M.D.
Head of FinanceMr. Lenaic Teyssedou
Head of Pharmaceutical Development & Member of Executive ManagementDr. Jean-Philippe Rocher Ph.D.